UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

[x]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

[X]QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2017March 31, 2019

 

[  ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

[  ]TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from __________ to __________

 

COMMISSION FILE NUMBER: 333-208293000-55753

 

CANBIOLA. INC.Canbiola. inc.


(Exact name of Registrant as specified in its charter)

 

Florida

Florida

20-3624118

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

960 South Broadway, Suite 120

Hicksville NY 11801

 (Address(Address of principal executive offices)

 

(516) 590-1846

(Registrant’s telephone number, including area code)

 

 (Former

(Former name, former address and former fiscal, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [x][X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [x][X] No [  ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer

[  ]

Accelerated filer

[  ]

Non-accelerated filer

[  ]

Smaller reporting company

[x]

X]

Emerging Growth Company

[x]

X]

(Do not check if smaller reporting company)

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [  ]Yes[x] [X] No


The number of shares of the registrant’s only class of common stock issued and outstanding as of November 16, 2017May 17, 2019 was 173,822,323552,992,664 shares.





CANBIOLA, INC.

FORM 10-Q

September 30, 2017

 

CANBIOLA, INC.

FORM 10-Q

March 31, 2019

TABLE OF CONTENTS

Page No.

Page No.

PART I. - FINANCIAL INFORMATION

Item 1.

Financial Statements

3

Consolidated Balance Sheets – September 30, 2017March 31, 2019 and December 31, 2016

2018

3

Consolidated Statements of Operations – Three and Nine Months Ended September 30, 2017March 31, 2019 and 2016

2018

4

Consolidated Statements of Cash Flows – Three and Nine Months Ended September 30, 2017March 31, 2019 and 2016

2018

6

5

Condensed Notes to Unaudited Consolidated Financial Statements.

7

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

18

23

Item 3.

3

Quantitative and Qualitative Disclosures About Market Risk.

19

24

Item 4.

4

Controls and Procedures.

19

24

PART II - OTHER INFORMATION

Item 1.

Legal Proceedings

20

24

Item 1A.

Risk Factors

20

24

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

20

24

Item 3.

Defaults Upon Senior Securities

21

25

Item 4.

Mine Safety Disclosures

21

25

Item 5.

Other Information

21

25

Item 6.

Exhibits

21

25


2

 





PART 1I - FINANCIAL INFORMATION


Item 1.Financial Statements.


 Canbiola, Inc. and Subsidiary

Consolidated Balance Sheets

 

 

September 30,

 

December 31,

 

 

2017

 

2016

 

 

(Unaudited)

 

 

Assets

 

 

 

 

Current assets:

 

 

 

 

   Cash and cash equivalents

 

$

4,225 

 

$

30,193 

   Accounts receivable, less allowance for doubtful

      accounts of $0 and $0, respectively

 

22,030 

 

13,742 

   Inventory

 

12,417 

 

   Prepaid expenses

 

62,134 

 

2,500 

   Total current assets

 

100,806 

 

46,435 

 

 

 

 

 

Property and equipment, at cost less accumulated

 

 

 

 

   depreciation of $19,442 and $17,021, respectively

 

11,954 

 

14,375 

 

 

 

 

 

Other assets:

 

 

 

 

   Security deposit

 

11,687 

 

11,687 

   Note receivable

 

39,000 

 

39,000 

   Intangible assets, net of accumulated

 

 

 

 

      amortization of $37,926 and $34,947, respectively

 

22,502 

 

25,481 

   Total other assets

 

73,189 

 

76,168 

 

 

 

 

 

Total assets

 

$

185,949 

 

$

136,978 

 

 

 

 

 

Liabilities and Stockholders' Equity

 

 

 

 

Current liabilities:

 

 

 

 

   Notes and loans payable

 

$

162,604 

 

$

58,315 

   Derivative Liability

 

279,928 

 

352,688 

   Accounts payable

 

135,683 

 

54,714 

   Accrued officers compensation

 

188,750 

 

134,750 

   Other accrued expenses payable

 

65,691 

 

51,099 

   Total current liabilities and total liabilities

 

832,656 

 

651,566 

Commitments and contingencies (Notes 7 and 12)

 

 

 

 

 

 

 

 

 

Stockholders' equity (deficit):

 

 

 

 

   Preferred stock, no par value; authorized 5,000,000 shares:  

      Series A Preferred stock, no par value:

 

 

 

 

         authorized 20 shares, issued and outstanding

 

 

 

 

         10 and 10 shares, respectively

 

103,664 

 

103,664 

   Common stock, no par value; authorized

 

 

 

 

      750,000,000 shares, issued and outstanding

 

 

 

 

      171,072,323 and 146,008,250 shares, respectively

 

12,223,631 

 

11,889,505 

   Accumulated deficit

 

(12,974,002)

 

(12,507,757)

   Total stockholders' equity (deficit)

 

(646,707)

 

(514,588)

 

 

 

 

 

Total liabilities and stockholders' equity (deficit)

 

$

185,949 

 

$

136,978 

See notes to consolidated financial statements.

 

 

 

 









Canbiola, Inc. and Subsidiary

Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

 

Nine Months Ended September 30,

 

Three Months Ended September 30,

 

 

2017

 

 

2016

 

 

2017

 

 

2016

Revenues

 

 

 

 

 

 

 

 

 

 

 

   Service Revenue

 

$

43,507 

 

 

$

71,990 

 

 

$

1,800 

 

 

$

24,327 

   Product Sales

 

22,433 

 

 

 

 

20,298 

 

 

Total Revenues

 

$

65,940 

 

 

$

71,990 

 

 

$

22,098 

 

 

$

24,327 

 

 

 

 

 

 

 

 

 

 

 

 

Operating cost and expenses:

 

 

 

 

 

 

 

 

 

 

 

   Cost of product sales

 

11,698 

 

 

 

 

10,559 

 

 

   Officers and directors compensation and payroll taxes (including

 

 

 

 

 

 

 

 

 

 

 

      stock - based compensation of $0, $0, $0 and $0 respectively

 

58,209 

 

 

159,463 

 

 

19,377 

 

 

38,897 

   Consulting fees (including stock-based compensation of $113,438

 

 

 

 

 

 

 

 

 

 

 

       $30,000, $76,209 and $0 respectively)

 

182,491 

 

 

98,473 

 

 

110,709 

 

 

4,104 

   Advertising expense

 

35,312 

 

 

10,301 

 

 

13,802 

 

 

5,551 

   Hosting expense

 

17,619 

 

 

20,465 

 

 

2,932 

 

 

8,325 

   Rent expense

 

48,795 

 

 

48,795 

 

 

16,265 

 

 

16,265 

   Professional fees

 

70,706 

 

 

36,787 

 

 

7,970 

 

 

20,050 

   Depreciation of property and equipment

 

2,421 

 

 

2,459 

 

 

807 

 

 

806 

   Amortization of intangible assets

 

2,979 

 

 

2,980 

 

 

993 

 

 

993 

   Other

 

81,161 

 

 

34,911 

 

 

20,642 

 

 

13,464 

 

 

 

 

 

 

 

 

 

 

 

 

   Total operating expenses

 

511,391 

 

 

414,634 

 

 

204,056 

 

 

108,455 

 

 

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

(445,451)

 

 

(342,644)

 

 

(181,958)

 

 

(84,128)

 

 

 

 

 

 

 

 

 

 

 

 

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

   Interest income

 

879 

 

 

877 

 

 

293 

 

 

292 

   Loss on debt conversion

 

(32,383)

 

 

 

 

(32,383)

 

 

   Income (expense) from derivative liability

 

252,010 

 

 

 

 

305,665 

 

 

   Interest expense (including amortization of debt discounts of $219,288, $0,

       $66,183 and $0 respectively)

 

(241,300)

 

 

(375)

 

 

(73,514)

 

 

(125)






 

 

 

 

 

 

 

 

 

 

 

 

   Other income (expense) – net

 

(20,794)

 

 

(502)

 

 

200,061

 

 

167 

 

 

 

 

 

 

 

 

 

 

 

 

Income (loss) before provision for income taxes

 

(466,245)

 

 

(342,142)

 

 

18,103

 

 

(83,961)

 

 

 

 

 

 

 

 

 

 

 

 

Provision for income taxes

 

 

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) and comprehensive income (loss)

 

$

(466,245)

 

 

$

(342,142)

 

 

$

18,103

 

 

$

(83,961)

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per common share – basic and diluted

 

 

 

 

 

 

 

 

 

 

 

   Basic

 

$

(0.00)

 

 

$

(0.00)

 

 

$

0.00

 

 

$

(0.00)

   Diluted

 

$

(0.00)

 

 

$

(0.00)

 

 

$

0.00

 

 

$

(0.00)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding –

 

 

 

 

 

 

 

 

 

 

 

   Basic

 

156,928,795 

 

 

146,009,710 

 

 

164,000,506

 

 

146,012,598 

   Diluted

 

273,703,025 

 

 

146,009,710 

 

 

289,732,512

 

 

146,012,598 

 

 

 

 

 

 

 

 

 

 

 

 

See notes to consolidated financial statements.










Canbiola, Inc. and Subsidiary

Consolidated Statements of Cash Flows

(Unaudited)

 

 

Nine Months Ended September 30,

 

 

2017

 

2016

Operating Activities:

 

 

 

 

 Net income (loss)

 

$

(466,245)

 

$

(342,142)

   Adjustments to reconcile net income (loss) to net

 

 

 

 

      cash used in operating activities:

 

 

 

 

      Stock-based compensation, net of prepaid stock based  

         consulting fees

 

113,438 

 

30,000 

      Loss on debt conversion

 

32,383 

 

      Expense (income) from derivative liability   

 

(252,010)

 

      Depreciation of property and equipment   

 

2,421 

 

2,460 

      Amortization of intangible assets

 

2,979 

 

2,980 

      Amortization of debt discounts

 

219,288 

 

   Changes in operating assets and liabilities:

 

 

 

 

      Accounts receivable

 

(8,288)

 

(2,981)

      Inventory

 

(12,417)

 

      Prepaid expenses

 

2,500 

 

9,671 

      Accounts payable

 

80,973 

 

66,819 

      Accrued officers compensation

 

54,000 

 

116,750 

      Other accrued expenses payable

 

25,760 

 

12,612 

 

 

 

 

 

   Net cash used in operating activities

 

(205,218)

 

(103,831)

 

 

 

 

 

Investing Activities:

 

 

 

 

   Net cash used in investing activities

 

 

 

 

 

 

 

Financing Activities:

 

 

 

 

   Proceeds received from notes and loans payable

 

179,250 

 

86,933 

 

 

 

 

 

   Net cash provided by financing activities

 

179,250 

 

86,933 

 

 

 

 

 

Increase (decrease) in cash and cash equivalents

 

(25,968)

 

(16,898)

 

 

 

 

 

Cash and cash equivalents, beginning of period

 

30,193 

 

18,373 

 

 

 

 

 

Cash and cash equivalents, end of period

 

$

4,225 

 

$

1,475 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

    Income taxes paid

 

$

 

$

Interest paid

 

$

 

$

 

 

 

 

 

NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

    Issuance of common stock in satisfaction of debt

 

$

115,000 

 

$

 

 

 

 

 

    Issuance of common stock in satisfaction of accrued interest

 

$

11,168 

 

$

 

 

 

 

 

    Issuance of common stock in satisfaction of accounts payable

 

$

 

$

47,174 

See notes to consolidated financial statements.

 

 

 

 








Canbiola, Inc. and Subsidiary

Consolidated Balance Sheets

  March 31, 2019  December 31, 2018 
Assets        
Current assets:        
Cash and cash equivalents $567,291  $807,747 
Accounts receivable, less allowance for doubtful
accounts of $0 and $0, respectively
  324,449   39,172 
Inventory  77,110   87,104 
Prepaid expenses - current  238,079   210,351 
Deposit - current  150,000   - 
Total current assets  1,356,929   1,144,374 
         
Property and equipment, at cost less accumulated depreciation of $34,738 and $20,248, respectively  743,368   59,619 
         
Other assets:        
Deposit - noncurrent  19,787   48,726 
Prepaid expenses - noncurrent  2,061,356   2,365,719 
Note receivable - noncurrent  19,389   19,389 
Intangible assets, net of accumulated amortization of $2,194 and $0, respectively  196,461   - 
Goodwill (Note 4)  55,849   55,849 
Right-of-Use Asset  90,591   - 
Total other assets  2,443,433   2,489,683 
         
Total assets $4,543,730  $3,693,675 
         
Liabilities and Stockholders’ Deficiency        
Current liabilities:        
Notes and loans payable $17,370  $19,205 
Accounts payable  126,747   73,059 
Accrued officers compensation  68,750   68,750 
Other accrued expenses payable  44,955   43,778 
Current portion of lease liability  31,466   - 
Total current liabilities  289,288   204,792 
         
Non-current portion of lease liability  59,125   - 
         
Total liabilities  348,413   204,792 
         
Commitments and contingencies (Notes 14)        
         
Stockholders’ deficiency:        
Preferred stock, authorized 5,000,000 shares:        
Series A Preferred stock, no par value: authorized 20 shares, issued and outstanding 17 and 18 shares, respectively  4,546,924   4,557,424 
Series B Preferred stock, $0.001 par value: authorized 500,000 shares, issued and outstanding 342,853 and 499,958 shares, respectively  322   479 
Common stock, no par value; authorized 750,000,000 shares, issued and outstanding 548,487,714 and 440,566,325 shares, respectively  18,531,529   16,624,557 
Additional Paid-in capital  872,976   872,976 
Additional Paid-in capital – Stock Options (Note 12)  202,200   202,200 
Accumulated deficit  (19,958,634)  (18,768,753)
Total stockholders’ deficiency  4,195,317   3,488,883 
         
Total liabilities and stockholders’ deficiency $4,543,730  $3,693,675 

See notes to consolidated financial statements.

3

Canbiola, Inc. and Subsidiary

Consolidated Statements of Operations and Comprehensive Loss

Three Months Ended March 31, 2019 and 2018

(Unaudited)

  2019  2018 
Revenues        
Product Sales $515,360  $62,969 
Service Revenue  1,800   6,800 
Total Revenues  517,160   69,769 
Cost of product sales  262,553   44,587 
Gross Profit  254,607   25,182 
         
Operating costs and expenses:        
Officers and directors compensation (including stock- based compensation of $262,420 and $202,800 respectively)  445,550   262,800 
Consulting fees (including stock-based compensation of $565,776 and $11,000, respectively)  663,751   275,908 
Advertising expense  26,388   22,333 
Hosting expense  450   3,668 
Rent expense  11,860   16,265 
Professional fees  37,836   13,383 
Depreciation of property and equipment  2,765   803 
Amortization of intangible assets  2,194   - 
Other  235,881   64,713 
         
Total operating expenses  1,426,675   659,873 
         
Loss from operations  (1,172,068)  (634,691)
         
Other income (expense):        
Interest income  -   2,512 
Income (expense) from derivative liability  -   1,075,706 
Interest expense (including amortization of debt discounts of $0 and $28,464, respectively)  (446)  (35,969)
         
Other income (expense) - net  (446)  1,042,249 
         
Income (Loss) before provision for income taxes  (1,172,514)  407,558 
         
Provision for income taxes  -   - 
         
Net income (loss) and comprehensive loss $(1,172,514) $407,558 
         
Net income (loss) per common share - basic and diluted $(0.00) $0.00 
         
Weighted average common shares outstanding –        
Basic  501,585,684   229,607,879 
Diluted  732,708,830   365,602,196 

See notes to consolidated financial statements.

4

Canbiola, Inc. and Subsidiary

Consolidated Statements of Cash Flows

(Unaudited)

  Three Months Ended March 31, 
  2019  2018 
Operating Activities:        
Net income $(1,172,514) $407,558 
Adjustments to reconcile net loss to net cash used in operating activities:        
Stock-based compensation, net of prepaid stock-
based consulting fees
  828,196   430,708 
Expense from derivative liability  -   (1,075,707)
Depreciation of property and equipment - General  2765   803 
Depreciation of property and equipment - COGS  5,198   - 
Amortization of intangible assets  2,194   - 
Amortization of debt discounts  -   28,464 
Changes in operating assets and liabilities:        
Accounts receivable  (285,277)  (5,720)
Inventory  9,994   1,172 
Security deposit  (121,061)  - 
Accounts payable  38,819   (52,274)
Accrued officers compensation  -   52,500 
Other accrued expenses payable  1,177   4,291 
         
Net cash used in operating activities  (690,509)  (208,205)
         
Investing Activities:        
Intangible assets additions  (50,000)  - 
Fixed assets additions  (694,212)  (13,330)
         
Net cash used in investing activities  (744,212)  (13,330)
         
Financing Activities:        
Repayments of notes and loans payable  (1,835)  - 
Proceeds received from notes and loans payable  -   25,000 
Proceeds from sale of common stock  1,196,100   - 
Proceeds from sale of Series B preferred stock  -   249,000 
         
Net cash provided by financing activities  1,194,265   274,000 
         
Increase (decrease) in cash and cash equivalents  (240,456)  52,465 
         
Cash and cash equivalents, beginning of period  807,747   1,652 
         
Cash and cash equivalents, end of period $567,291  $54,117 
         
SUPPLEMENTAL CASH FLOW INFORMATION:        
Income taxes paid $-  $- 
Interest paid $-  $- 
         
NON-CASH INVESTING AND FINANCING
ACTIVITIES:
        
        
Issuance of common stock in acquisition of Intangible assets $148,655  $- 
Issuance of common stock in satisfaction of Officers compensation $54,340  $- 
Issuance of common stock in satisfaction of directors fees $-  $202,800 
Issuance of common stock for services rendered $497,220  $- 

See notes to consolidated financial statements.

5

Canbiola, Inc. and Subsidiary

Notes to Consolidated Financial Statements

Three Months Ended September 30, 2017March 31, 2019 and 20162018

(Unaudited)


NOTE 1 – Organization and Description of Business


Canbiola, Inc. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), a New York corporation incorporated on April 2, 2008. On May 15, 2017, WRAP changed its name to Canbiola, Inc. (the “Company” or “CANB” or “Canbiola”). The Company operates several divisions, including document management and email marketing platforms and a division specializing in the sale of products containing CBD. The Company used to operate its document and information platform from its wholly owned subsidiary, Prosperity Systems, Inc (“Prosperity”); however, after the acquisition of Prosperity, the Company transferred Prosperity’s operations to WRAP and is presently in the process of dissolving Prosperity. ForThe Company acquired 100% of the periods presented,membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company formed Duramed, Inc., a Nevada corporation (“Duramed”) in November 2018, to facilitate the assets, liabilities, revenues,manufacture and expenses are thosesale of CANB. Prosperity had no activity for the periods presented. durable medical equipment incorporating CBD.

Effective December 27, 2010, WRAP effected a 10 for 1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1 for 10 reverse stock split of its common stock. The accompanying consolidated financial statements retroactively reflect these stock splits.


On May 15, 2017, WRAP changed its name to Canbiola, Inc. (the “Company” or “CANB” or “Canbiola”).

Canbiola Inc. is a US Company specializingspecializes in the production and sale of a variety of hemp derived Cannabidiol (Hemp) based(“CBD”) products such as oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola is developing theirits own line of proprietary products as well as seeking synergistic value through acquisitions in the Hemp Industry. Canbiola aims to be the premier provider of the highest quality Hemp naturalhemp CBD products on the market through sourcing the very best raw material and developing a variety of products we believe will improve people'speople’s lives in a variety of areas.

The Company also operates document management and email marketing platforms. The Company used to operate its document and information platform from its wholly owned subsidiary, Prosperity Systems, Inc; however, after the acquisition of Prosperity, the Company transferred Prosperity’s operations to the Company directly.

For the periods presented, the assets, liabilities, revenues, and expenses are those of CANB. Prosperity had no activity for the periods presented. Financial information for PHP and Duramed in the periods have been consolidated with the Company’s financials.


NOTE 2 – Going Concern Uncertainty


The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of assets and liquidation of liabilities in a normal course of business. As of September 30, 2017,March 31, 2019, the Company had cash and cash equivalents of $4,225$567,291 and negativea working capital of $731,850.$1,067,641. For the ninethree months ended September 30, 2017March 31, 2019 and 2016,2018, the Company had net lossesloss of $466,245$1,172,514 and $342,142,a gain of $407,558, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern. The Company plans to improve its financial condition by raising capital through sales of shares of its common stock. Also, the Company plans to start a health supplements businessexpand its operation of CBD products to attain profitable operations.increase its profitability. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.


NOTE 3 – Interim Financial Statements


The accompanying unaudited consolidated financial statements have been prepared by the Company pursuant to the rules and regulations of the Securities and Exchange Commission. Accordingly, they may not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. The interim financial statements should be read in conjunction with the Company’s latest annual financial statement. In the opinion of management, the unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary for a fair presentation. Operating results for the three-month period ended September 30, 2017 may not necessarily be indicative of the results that may be expected for the year ending December 31, 2017.


NOTE 43 – Summary of Significant Accounting Policies


(a) Principles of Consolidation

 

The consolidated financial statements include the accounts of CANB and its wholly owned subsidiary Prosperity from the date of its acquisition on January 5, 2015.subsidiaries, Pure Health products, Duramed, and Prosperity. All intercompany balances and transactions have been eliminated in consolidation.

 

6

(b) Use of Estimates


The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.






(c) Fair Value of Financial Instruments


The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, notenotes receivable, notes and loans payable, accounts payable, and accrued expenses payable. Except for the noncurrent note receivable, the fair value of these financial instruments approximate their carrying amounts reported in the consolidated balance sheets due to the short term maturity of these instruments. Based on comparable instruments with similar terms, the fair value of the noncurrent note receivable approximates its carrying value.


Pursuant to ASC 820, Fair Value Measurements and Disclosures, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:


Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.


Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.


Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.


(d) Cash and Cash Equivalents


The Company considers all liquid investments purchased with a maturity of three months or less to be cash equivalents.


(e) Inventory


All inventories are finished goods and stated at the lower of cost or market.net realizable value. Cost is principally determined using the first-in, first-out (FIFO) method.


(f) Property and Equipment, Net


Property and equipment, net, is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the respective assets. Maintenance and repairs are charged to operations as incurred.


(g) Intangible Assets, Net


Intangible assets, net, are stated at cost less accumulated amortization. Amortization is calculated using the straight-line method over the estimated economic lives of the respective assets.


7

(h) Goodwill and Intangible Assets with Indefinite Lives


The Company does not amortize goodwill and intangible assets with indefinite useful lives, but instead tests for impairment at least annually. When conducting the annual impairment test for goodwill, the Company compares the estimated fair value of a reporting unit containing goodwill to its carrying value. If the estimated fair value of the reporting unit is determined to be less than its carrying value, goodwill is reduced, and an impairment loss is recorded.


(i) Long-lived Assets


The Company reviews long-lived assets held and used, intangible assets with finite useful lives and assets held for sale for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset is compared to the asset’s carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.

 

(j) Revenue Recognition


The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over agreed periodstime or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Private Label Customers, Global CBD, LLC and TZ Wholesale, are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to customers, provided thereCompany specifications, and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are no uncertainties regarding customer acceptance, persuasive evidence offully paid when shipped.

Revenue from product sales is recognized when an arrangement exists;order has been obtained, the sales price is fixed or determinable;and determinable, the product is shipped, title has transferred, and collectability is deemed probable.reasonably assured.





The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35 day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis.

(k) Cost of Product Sales

The cost of product sale is the total cost incurred to obtain a sale and the cost of the goods sold, and the Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of product sale primarily consisted of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products.

8

(l) Stock-Based Compensation


Stock-based compensation is accounted for at fair value in accordance with Accounting Standards Codification (“ASC”) Topic 718, “Compensation – Stock Compensation” (“ASC718”) and ASC 505-50, Equity“Equity – Based Payments to Non-Employees.


In addition to requiring supplemental disclosures, ASC 718 addresses the accounting for share-based payment transactions in which a company receives goods or services in exchange for (a) equity instruments of the company or (b) liabilities that are based on the fair value of the company’s equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 focuses primarily on accounting for transactions in which a company obtains employee services in share-based payment transactions.


In accordance with ASC 505-50, the Company determines the fair value of the stock based payment as either the fair value of the consideration received or the fair value of the equity instruments issued, whichever is more reliably measurable. If the fair value of the equity instruments issued is used, it is measured using the stock price and other measurement assumptions as of the earlier of either (1) the date at which a commitment for performance by the counterparty to earn the equity instrument is reached, or (2) the date at which the counterparty’s performance is complete.


Options and warrants


The fair value of stock options and warrants is estimated on the measurement date using the Black-Scholes model with the following assumptions, which are determined at the beginning of each year and utilized in all calculations for that year:


·

Risk-Free Interest Rate.


We utilized the U.S. Treasury yield curve in effect at the time of grant with a term consistent with the expected term of our awards.


·

Expected Volatility.


We calculate the expected volatility based on a volatility index of peer companies as we did not have sufficient historical market information to estimate the volatility of our own stock.


·

Dividend Yield.


We have not declared a dividend on its common stock since its inception and have no intentions of declaring a dividend in the foreseeable future and therefore used a dividend yield of zero.


·

Expected Term.


The expected term of options granted represents the period of time that options are expected to be outstanding. We estimated the expected term of stock options by using the simplified method. For warrants, the expected term represents the actual term of the warrant.


·

Forfeitures.


Estimates of option forfeitures are based on our experience. We will adjust our estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.


9

(l)

(m) Advertising


Advertising costs are expensed as incurred and amounted to $35,312$26,388 and $10,301$22,333 for the nine monthsperiod ended September 30, 2017March 31, 2019 and 2016,2018, respectively.


(m)(n) Research and Development


Research and development costs are expensed as incurred. In the period ended March 31, 2019 and 2018, the Company spent $17,500 and $2,500 in research and development which was expenses as spent, respectively.






(n)(o) Income Taxes


Income taxes are accounted for under the assets and liability method. Current income taxes are provided in accordance with the laws of the respective taxing authorities. Deferred income taxes are provided for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is not more likely than not that some portion or all of the deferred tax assets will be realized.


The Company has adopted the provisions required by the Income Taxes topic of the FASB Accounting Standards Codification. The Codification Topic requires the recognition of potential liabilities as a result of management’s acceptance of potentially uncertain positions for income tax treatment on a “more-likely-than-not” probability of an assessment upon examination by a respective taxing authority. The Company believes that it has not taken any uncertain tax positions and thus has not recorded any liability.


(o)(p) Net Income (Loss) per Common Share


Basic net income (loss) per common share is computed on the basis of the weighted average number of common shares outstanding during the period.


Diluted net income (loss) per common share is computed on the basis of the weighted average number of common shares and dilutive securities (such as stock options and convertible securities) outstanding. Dilutive securities having an anti-dilutive effect on diluted net income (loss) per share are excluded from the calculation. For the three and nine months ended September 30, 2016,periods presented, the diluted net loss per share calculation excluded the effect of convertible notes payable, Series AB preferred stockstocks and stock options outstanding (see Notes 7, 8 and 10).


(p)(q) Recent Accounting Pronouncements


Certain accounting pronouncements have been issued by the FASB and other standard setting organizations which are not yet effective and therefore have not yet been adopted by the Company.  These include:


In AugustMay 2014, the FASB issued ASU 2014-15 “Disclosure about an Entity’s Ability to Continue as a Going Concern”.2014-09 “Revenue from Contracts with Customers” (Topic 606) which establishes revenue recognition standards. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017. The update establishes management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern including related disclosures.impact of ASU 2014-09 on the Company’s financial statements has not been significant.


In 2016, the FASB issued ASU 2016-2 (topic(Topic 842) which establishes a new lease accounting model for lessees. Under the new guidance, lessees will be required to recognize right of use assets and liabilities for most leases having terms of 12 months or more. Effective January 1, 2019, we adopted this new accounting guidance using the effective date transition method, which permits entities to apply the new lease standards using a modified retrospective transition approach at the date of adoption. As such, historical periods will continue to be measured and presented under the previous guidance while current and future periods subject to this new accounting guidance. Upon adoption we recorded a $100,681 right-of-use asset related to our one operating lease (see Note 13) and a $90,591 lease liability.

 

The impact on the Company’s financial statements has not yet been determined.


(q)(r) Reclassifications


Certain amounts in the prior periodyear consolidated financial statements have been reclassified to conform to the current year presentation. These reclassification adjustments had no effect on the Company'sCompany’s previously reported net income.


10



NOTE 4 – Acquisition of Pure Health Products, LLC

Effective December 28, 2018, CANB acquired 100% ownership of Pure Health Products, LLC (“Pure Health”) in exchange for the cancellation of CANB’s $75,000 note receivable from Pure Health and $10,827 accrued interest thereon and issuance of 3,096,827 newly issued shares of CANB common stock (valued at the $0.0578 closing trading price on December 28, 2018 or $178,997, see Note 11). The acquisition has been accounted for in the accompanying consolidated financial statements as a purchase transaction. Accordingly, the financial position and results of operations of Pure Health prior to the date of the acquisition have been excluded from the accompanying consolidated financial statements.

The estimated fair values of the identifiable net assets of Pure Health at December 28, 2018 (effective date of acquisition) consisted of:

Cash and cash equivalents $404 
Accounts receivable from CANB  16,676 
Inventory  79,652 
Property and equipment, net  7,559 
     
Security deposit  2,100 
     
Total assets  106,391 
     
Accounts payable, including $34,419 due to CANB  49,825 
     
Total liabilities  49,825 
     
Identifiable net assets $56,566 

Goodwill of $55,849 (excess of the $112,415 fair value of the 3,096,827 shares of CANB common stock issued to Pure Health’s stockholders over the $56,566 identifiable net assets of Pure Health at December 28, 2018 after reflecting the $85,827 cancellation of the $75,000 note payable and $10,827 accrued interest) was recorded from the acquisition.

The following pro forma information summarizes the results of operations for the periods indicated as if the acquisition occurred at December 31, 2017. The pro forma information is not necessarily indicative of the results that would have been reported had the transaction actually occurred on December 31, 2017, nor is it intended to project results of operations for any future period.

  Three Months Ended 
  March 31, 
  2019  2018 
       
Product sales $515,360  $67,207 
         
Cost of product sales  262,553   42,607 
         
Gross profit on product sales  252,807   24,600 
         
Service revenue  1,800   6,800 
         
Total gross profit  254,607   31,400 
         
Operating expenses  1,426,675   673,665 
         
Loss from operations  (1,172,068)  (642,265)
         
Other income (loss) - net  (446)  1,042,249 
         
Net income (loss) $(1,172,514) $399,984 
Net income (loss) per common share- basic and diluted $(0.00) $0.00 
         
Weighted average common shares outstanding –        
Basic  501,585,684   229,607,879 
Diluted  732,708,830   365,602,196 


11


NOTE 5 – NoteInventories

Inventories consist of:

 March 31, 2019  December 31, 2018 
Raw materials $72,148  $79,652 
         
Finished goods  4,962   7,452 
Total $77,110  $87,104 

NOTE 6 – Notes Receivable


At September 30, 2017 and December 31, 2016, the $39,000 noteNotes receivable bears interest at a rate of 3% per annum and is due November 30, 2020. The receivable arose from the Company’s sale of its 50% interest in consist of:

 March 31, 2019  December 31, 2018 
Note receivable dated November 30, 2015 from Stock Market Manager, Inc, interest at 3% per annum due November 30, 2020 $19,389  $19,389 
         
Total  19,389   19,389 
         
Current portion of notes receivable  -   - 
Noncurrent portion of notes receivable $19,389  $19,389 

Stock Market Manager, Inc. to Endeavour Cooperative Partners, LLC (“Endeavour”) on November 30, 2015. EndeavourInc is affiliated with Carl Dilley, a Company director. In 2018, the Company received services from Stock Market Manager valued at $19,611 in exchange for the cancellation of $19,611 in note receivables.

12

NOTE 7 – Property and Equipment, Net

Property and Equipment, net, consist of:

  March 31, 2019  December 31, 2018 
       
Furniture & Fixtures $19,018  $19,018 
         
Office Equipment  12,378   20,992 
         
Manufacturing Equipment  746,710   46,384 
         
Total  778,106   86,394 
         
Accumulated amortization  (34,738)  (26,775)
         
Net $743,368  $59,619 


NOTE 68 – Intangible Assets, Net


Intangible assets, net, consist of:


 

 

September 30,

 2017

 

December 31, 2016

Video conferencing software acquired

  by Prosperity in December 2009

 

$

30,000 

 

$

30,000 

 

 

 

 

 

Enterprise and audit software acquired

  by Prosperity in April 2008

 

20,000 

 

20,000 

 

 

 

 

 

Patent costs incurred by CANB

 

6,880 

 

6,880 

 

 

 

 

 

Other

 

3,548 

 

3,548 

 

 

 

 

 

Total

 

60,428 

 

60,428 

 

 

 

 

 

Accumulated amortization

 

(37,926)

 

(34,947)

 

 

 

 

 

Net

 

$

22,502 

 

$

25,481 

  March 31, 2019  December 31, 2018 
       
Video conferencing software acquired by Prosperity in December 2009 $30,000  $30,000 
         
Enterprise and audit software acquired by Prosperity in April 2008  20,000   20,000 
         
Patent costs incurred by WRAP  6,880   6,880 
         
CBD Technology  198,655   - 
         
Other  3,548   3,548 
         
Total  259,083   60,428 
         
Accumulated amortization and Impairment  (60,428)  (60,428)
         
Net $198,655  $0 


Expected future amortization expenseThe CBD related technology were purchased from Hudilab, Inc. (“HUDI”) and Seven Chakras, LLC (“Seven Chakras”) in the three months ended March 31, 2019. On January 14, 2019, the Company and PHP (collectively, the “buyer”) entered into a License and Acquisition Agreement (the “LAA”) with HUDI. Pursuant to the LAA, HUDI will sell the technology owned by it to the buyer in exchange for 7,500,000 shares of CANB common stock. On January 14, 2019, the shares were issued to the owner of HUDI and valued at $131,625. On January 31, 2019, PHP entered into an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC (“Seven Chakras”). Pursuant to the Agreement, PHP purchased the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ products containing cannabidiol (“CBD”), (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials (collectively, the “Assets”). On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock valued at $17,030 to owners of Seven Chakras as additional consideration, along with the $50,000 cash payments, pursuant to the agreement.

13

The other intangible assets asrelate to the document management and email marketing divisions. Since December 31, 2017, the Company do not expect any future positive cash flow from these divisions. Accordingly, the net carrying value of September 30, 2017 follows:these intangible assets was reduced to $0.


Amount

Year Ending December 31, 2017

$

995

Year Ending December 31, 2018

3,975

Year Ending December 31, 2019

3,975

Year Ending December 31, 2020

3,975

Year Ending December 31, 2021

3,975

Thereafter

5,607

Total

$

22,502






NOTE 79 – Notes and Loans Payable


Notes and loans payable consist of:


 

 

September 30,

 2017

 

December 31, 2016

Convertible note payable to lender dated February 1, 2016 (as amended         

        December 21, 2016), interest at 12% per annum, due February 1,

        2017, convertible into Common Stock at a Conversion Price equal to the

        Lesser of (i) $0.01 per share or (ii) 50% of the lowest Bid Price of the

        Common Stock for the 30 Trading Days preceding the Conversion Date       

        –fully converted at February 13, 2017

 

$

-

 

$

3,571

 

 

 

 

 

Convertible notes payable to lender dated from March 15, 2016 (as amended June 2, 2016) to September 13, 2017, interest at rates ranging from 12% to 14.99% per annum, due from April 6, 2017 to March 13, 2018, partially converted at March 22, 2017 and the remaining notes convertible into Common Stock at a Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of the lowest Closing Bid Price of the Common Stock for the 30 Trading Days preceding the Conversion Date – net of

        unamortized debt discount of $1,643 and $34,411, respectively   

 

35,357

 

39,839

 

 

 

 

 

Convertible notes payable to lender dated February 1, 2016 (as amended

        December 21, 2016) and December 21, 2016, interest at 12% per

        annum, due February 1, 2017 and May 20, 2017, convertible into

        Common Stock at a Conversion Price equal to the lesser of (i) $0.01 per

        share or (ii) 50% of the lowest Closing Bid Price of the Common Stock

        for the 30 Trading Days preceding the Conversion Date – net of

        unamortized debt discount of $0 and $58,095, respectively     

 

65,000

 

6,905

 

 

 

 

 

Convertible notes payable to Pasquale and Rosemary Ferro dated from

        May 2, 2017 to November 3, 2017, interest at 12% per annum, due from

        September 16, 2017 to May 7, 2018, convertible into Common Stock at a

        Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of

        the lowest Closing Bid Price of the Common Stock for the 30 Trading

        Days preceding the Conversion Date – net of unamortized debt discount

        of $40,883 and $0, respectively     

 

50,617

 

-

 

 

 

 

 

Convertible note payable to lender dated August 8, 2017 interest at 12% per

        annum, due August 8, 2018, convertible into Common Stock at a

        Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of

        the lowest Closing Bid Price of the Common Stock for the 30 Trading

        Days preceding the Conversion Date – net of unamortized debt discount

        of $21,370 and $0, respectively     

 

3,630

 

-

 

 

 

 

 

Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due)

 

5,000

 

5,000

 

 

 

 

 

Loan payable to Mckenzie Webster Limited (“MWL”), an entity controlled by the former Chairman of the Board of Directors of the Company, non-interest bearing, due on demand

 

3,000

 

3,000

Total

 

$

162,604

 

$

58,315

 March 31, 2019  December 31, 2018 
Note payable to brother of Marco Alfonsi, Chief Executive Officer of the Company, interest at 10% per annum, due August 22, 2016 (now past due)  5,000   5,000 
         
Note payable to Carl Dilley, a director of the Company, interest at 12.99% per annum, due February 1, 2021  10,899   10,899 
         
Loan payable to Mckenzie Webster Limited (“MWL”), an entity controlled by the former Chairman of the Board of Directors of the Company, non-interest bearing, due on demand  3,000   3,000 
         
Total $18,899  $18,899 






The derivative liability of the convertible notes payable at September 30, 2017 consisted of:


 

 

Face Value

 

Derivative Liability

Convertible notes payable to lender dated from March 15, 2016 (as amended June 2, 2016) to September 13, 2017, due from April 6, 2017 to March 13, 2018

 

$

37,000

 

$

39,539

 

 

 

 

 

Convertible notes payable to lender dated February 1, 2016 (as amended

        December 21, 2016) and December 21, 2016, due February 1, 2017 and

        May 20, 2017

 

$

65,000

 

$

67,889

 

 

 

 

 

Convertible notes payable to Pasquale and Rosemary Ferro dated from

        May 2, 2017 to November 3, 2017, due from September 16, 2017 to

        May 7, 2018  

 

$

91,500

 

$

128,056

 

 

 

 

 

Convertible notes payable to lender dated August 8, 2017, due August 8,

        2018

 

$

25,000

 

$

44,444

 

 

 

 

 

Totals

 

$

218,500

 

$

279,928


The above convertible notes contain a variable conversion feature based on the future trading price of the Company common stock. Therefore, the number of shares of common stock issuable upon conversion of the notes is indeterminate. Accordingly, we have recorded the fair value of the embedded conversion features as a derivative liability at the respective issuance dates (or amendment dates) of the notes ($437,575 total for the nine months ended September 30, 2017) and charged the applicable amounts to debt discounts ($179,250 total for the nine months ended September 30, 2017) and the remainder to other expense ($258,325 total for the nine months ended September 30, 2017). The increase (decrease) in the fair value of the derivative liability from the respective issuance dates (or amendment dates) of the notes to the measurement date ($236,854 total decrease for the nine months ended September 30, 2017) is charged (credited) to other expense (income). The fair value of the derivative liability of the notes is measured at the respective issuance dates and quarterly thereafter using the Black Scholes option pricing model. Assumptions used for the calculations of the derivative liability of the notes at September 30, 2017 include (1) stock price of $0.0092 per share, (2) exercise price of $0.0045 per share, (3) terms ranging from 0 days to 312 days, (4) expected volatility of 281% and (5) risk free interest rates ranging from 0.00% to 1.28%.


NOTE 89 – Preferred Stock


The Company issued a total of 10 shares of CANB Series A Preferred Stock (5 shares to MWL and 5 shares to Marco Alfonsi) in exchange for the retirement of a total of 100,000,000 shares of CANB common stock (50,000,000 shares from MWL and 50,000,000 shares from Marco Alfonsi).


Each share of Series A Preferred Stock is convertible into 10,000,000 shares of CANB common stock and is entitled to 20,000,000 votes.


NOTE 9 – CommonEach share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights.


On January 2, 2016,22, 2018, the Company issued 104,50087,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share.

On February 12, 2018, the Company issued 1 share of CANB Series A Preferred Stock to David Posel pursuant to a service agreement. The fair value of the issuance is $373,000 and will be amortized over the vesting period of four years.

On February 16, 2018, the Company issued 3 shares of CANB Series A Preferred Stock to Andrew Holtmeyer pursuant to a service agreement. The fair value of the issuance is $1,020,000 and will be amortized over the vesting period of one year.

On February 16, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share.

On March 20, 2018, the Company issued 87,368 shares of CANB Series B Preferred Stock to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $83,000, or $0.95 per CANB Series B Preferred share.

On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, RedDiamond Partners converted its 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock to 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock, respectively.

14

On May 14, 2018, the Company issued 1 share of CANB Series A Preferred Stock to a consultant pursuant to a Consulting Agreement dated May 11, 2018. The $150,000 fair value of the issuance was partially charged to consulting fees in the three months ended September 30, 2018.

From July 24, 2018 to September 26, 2018, RedDiamond Partners converted aggregately 263,263 shares of CANB Series B Preferred Stock to 53,839,743 shares of CANB common stock.

On August 28, 2018, September 14, 2018 and September 19, 2018, the Company issued 36,842 shares, 105,263 shares, and 105,263 shares of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) pursuant to an amended Securities Purchase Agreement dated January 9, 2018, in exchange for proceeds of $35,000, $100,000 and $100,000, respectively, or $0.95 per CANB Series B Preferred share.

From October 2, 2018 to November 7, 2018, RedDiamond Partners converted aggregately 101,736 shares of CANB Series B Preferred Stock to 13,094,733 shares of CANB common stock.

On October 23, 2018 and November 14, 2018, the Company issued 200,000 shares and 52,500 shares of CANB Series B Preferred Stock, respectively, to RedDiamond Partners LLC (“RedDiamond”) in exchange for proceeds of $190,000 and $49,875, respectively, or $0.95 per CANB Series B Preferred share.

On December 28,2018, Marco Alfonsi converted 3 shares of CANB Series A Preferred Stock to 30,000,000 shares of CANB common stock.

On December 29, the Company issued 8 shares of CANB Series A Preferred Stock to three officers of the company (1 share to Stanley L. Teeple, 5 shares to Pasquale Ferro and 2 shares to Andrew Holtmeyer), pursuant to the employment agreements with them. The fair value of the issuance totaled at $4,624,000 and will be amortized over the vesting period of four years.

On January 28, 2019, the Company issued 10,000,000 shares of CANB common stock to a technical consultant of the Company in satisfactionexchange for the retirement of a $12,864 account payable1 share of CANB Series A Preferred Stock.

From February 21, 2019 to that vendor.


On March 9, 2016,12, 2019, the Company issued 140,000aggregately 20,221,436 shares of CANB common stock to RedDiamond in exchange for the retirement of 157,105 shares of CANB Series B Preferred Stock.

NOTE 11 – Common Stock

On February 7, 2018, the Company issued 250,000 shares of CANB common stock to a technical consultant for services rendered. The $9,825 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in satisfaction of a $8,693 account payable to that vendor.the three months ended March 31, 2018.


On October 6, 2016,February 9, 2018, the Company issued 400,0003,000,000 and 3,000,000 shares of CANB common stock to its two directors for services rendered, respectively. The $101,400 fair value of each 3,000,000 shares of CANB common stock was charged to directors fees in the three months ended March 31, 2018. The shares issued to one of the directors were converted to options at June 11, 2018 (see Note 10).

On February 13, 2018, the Company issued 150,000 shares of CANB common stock to a technical consultant for services rendered. The $5,085 fair value of the 150,000 shares of CANB common stock was partially charged to consulting fees in satisfaction of a $25,617 account payable to that vendor.the three months ended March 31, 2018.


On February 2, 2017,14, 2018, the Company issued 200,000250,000 shares of CANB common stock to a financial consultant for services rendered. The $11,000$8,500 fair value of the 200,000250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.

15

On February 19, 2018, the Company issued 150,000 shares of CANB common stock to a consultant for services rendered. The $5,280 fair value of the 150,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.

On February 26, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,375 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended March 31, 2018.

On March 1, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,900 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended March 31, 2017.2018.


On February 13, 2017, the Company issued 1,685,900 shares of CANB common stock to the brother of the Chief Executive Officer of the Company in satisfaction of notes payable of $15,000 and accrued interest payable of $1,859.


On March 22, 2017, the Company issued 6,785,316 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $5,979.






On April 17, 2017, the Company issued 5,000,000 shares of CANB common stock to a consultant for services rendered. The $103,500 fair value of the 5,000,000 shares of CANB common stock will be charged to consulting fees in the three months ended June 30, 2017.


On June 21, 2017,20, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,975$6,500 fair value of the 250,000 shares of CANB common stock will bewas charged to consulting fees in the three months ended March 31, 2018.

On April 13, 2018, April 25, 2018, May 3, 2018, June 19, 2018 and June 25, 2018, the Company issued 1,287,129 shares, 1,287,129 shares, 1,287,129 shares, 3,545,455 shares, and 2,363,636 shares of CANB common stock to RedDiamond in exchange for the retirement of 10,000 shares, 10,000 shares, 10,000 shares, 15,000 shares and 10,000 shares of CANB Series B Preferred Stock, respectively.

On May 9, 2018, the Company issued 125,000 shares of CANB common stock to a consultant for services rendered.. The $1,812 fair value of the 125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2017.2018.


On June 28, 2017,May 29, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $5,000 fair value of the 250,000 shares of CANB common stock will bewas partially charged to consulting fees in the three months ended June 30, 2017.2018.


On August 25, 2017, the Company issued 7,142,857 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $3,331.


On August 25, 2017,May 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,750$4,600 fair value of the 250,000 shares of CANB common stock will be partiallywas charged to consulting fees in the three months ended SeptemberJune 30, 2017.2018.


On September 5, 2017,June 4, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,375$5,750 fair value of the 250,000 shares of CANB common stock will bewas partially charged to consulting fees in the three months ended June 30, 2018.

On June 11, 2018, the Company agreed to issue 2,749,429 shares of CANB common stock to a lender in satisfaction of notes payable of $15,000 and accrued interest payable of $4,246. The shares was issued at August 24, 2018.

On June 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $6,250 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended June 30, 2018.

On June 22, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $8,250 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended June 30, 2018.

From July 24, 2018 to September 26, 2018, the Company issued aggregately 53,839,743 shares of CANB common stock to RedDiamond in exchange for the retirement of 263,263 shares of CANB Series B Preferred Stock.

On July 31, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,225 fair value of the 250,000 shares of CANB common stock was charged to consulting fees in the three months ended September 30, 2018.

16

On August 9, 2018, Company received a conversion notice from a lender. As a result, 9,544,292 shares of CANB common stock was issued to the lender in satisfaction of notes payable of $50,000 and accrued interest payable of $7,266 at August 21, 2018.

On August 28, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $159,600 fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2017.2018.


On September 7, 2017,6, 2018, the Company issued 2,500,000300,000 shares of CANB common stock to a consultant for services rendered. The $32,750$16,500 fair value of the 2,500,000300,000 shares of CANB common stock will be charged to consulting fees in the three months ended September 30, 2017.


On September 11, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered, respectively. The $3,350 fair value of each 250,000 shares of CANB common stock will bewas partially charged to consulting fees in the three months ended September 30, 2017.2018.


On September 25, 2017,6, 2018, the Company issued 2,500,000500,000 shares of CANB common stock to a consultant for services rendered. The $2,525$27,500 fair value of the 2,500,000500,000 shares of CANB common stock will bewas charged to consulting fees in the three months ended September 30, 2018.

On September 6, 2018, the Company issued 8,430,331 shares of CANB common stock to a lender in satisfaction ofnotes payable of $38,500 and accrued interest payable of $7,867.

On September 7, 2018, the Company issued 5,121,694 shares of CANB common stock to a lender in satisfaction ofnotes payable of $25,000 and accrued interest payable of $3,169.

On September 7, 2018, the Company issued 10,045,667 shares of CANB common stock to a lender in satisfaction ofnotes payable of $50,000 and accrued interest payable of $10,274.

On September 8, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $11,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2017.2018.

On September 10, 2018, the Company issued 500,000 shares of CANB common stock to a consultant for services rendered. The $19,950 fair value of the 500,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 17, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $10,750 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 18, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $13,725 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 20, 2018, the Company issued 7,407,407 shares of CANB common stock to an investor pursuant to a Stock Purchase Agreement dated September 17, 2018, in exchange for proceeds of $200,000, or $0.027 per CANB common share.

On September 21, 2018, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $14,500 fair value of the 250,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

On September 25, 2018, the Company issued 2,000,000 shares of CANB common stock to a consultant for services rendered. The $97,400 fair value of the 2,000,000 shares of CANB common stock was partially charged to consulting fees in the three months ended September 30, 2018.

From October 2, 2018 to November 7, 2018, the Company issued aggregately 13,094,733 shares of CANB common stock to RedDiamond in exchange for the retirement of 101,736 shares of CANB Series B Preferred Stock.

17

From November 5, 2018 to December 28, 2018, the Company issued aggregately 2,125,000 shares of CANB common stock to multiple consultants for services rendered. The $80,665 fair value of the 2,125,000 shares of CANB common stock was partially charged to consulting fees in the three months ended December 30, 2018.

From December 3, 2018 to December 28, 2018, the Company issued aggregately 1,500,000 shares of CANB common stock to three board members for services rendered. The $62,342 fair value of the 1,500,000 shares of CANB common stock was charged to director fees in the three months ended December 30, 2018.

From December 3, 2018 to December 28, 2018, the Company issued aggregately 22,413,794 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $650,000.

On December 11, 2018, the Company issued 891,089 shares of CANB common stock to RedDiamond in satisfaction of dividend payable of $9.000.

On December 19, 2018, the Company issued 891,089 shares of CANB common stock to Auctus, LLC pursuant to a cashless exercise of stock options.

On December 21, 2018, Company received a conversion notice from a lender. As a result, 9,372,100 shares of CANB common stock was issued to the lender in satisfaction of notes payable of $83,500 and accrued interest payable of $10,221.

On December 21, 2018, Company issued aggregately 4,370,629 shares of CANB common stock to four officers of the Company in satisfaction of accrued compensation of $192,300.

On December 28, 2018, the Company issued 3,096,827 shares of CANB common stock for the acquisition of Pure Health Products, LLC.

On December 28, 2018, the Company issued 245,789 shares of CANB common stock to an officer of the Company pursuant to the Employment Agreement dated December 29, 2018 with Andrew Holtmeyer. The $10,371 fair value of the issuance was charged to stock-based compensation in the three months ended December 31, 2018.

On December 29, the Company issued 30,000,000 shares of CANB common stock to Marco Alfonsi in exchange for the return of 3 shares of CANB Series A Preferred Stock owned by Marco Alfonsi.

From January 4, 2019 to March 27, 2019, the Company issued aggregately 41,431,994 shares of CANB common stock to multiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in exchange for total proceeds of $1,196,100.

On January 14, 2019, the Company issued 7,500,000 shares of CANB common stock to Hudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for purchase of the technology owned by HUDI.

From January 18, 2019 to March 17, 2019, the Company issued aggregately 24,600,000 shares of CANB common stock to multiple consultants for services rendered.

From January 19, 2019 to March 27, 2019, the Company issued aggregately 1,167,959 shares of CANB common stock to employee and officers of the Company pursuant to employee agreement and in satisfaction of accrued compensation for the quarter ended March 31, 2019.

On February 5, 2019, the Company issued 2,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018.

On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to owners of Seven Chakras pursuant to an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC dated January 31, 2019.


NOTE 1012 – Stock Options and Warrants


A summary of stock options and warrants activity follows:


 

Shares of Common Stock Exercisable Into

 

Stock

 

 

 

 

 

Options

 

Warrants

 

Total

Balance, December 31, 2015

200,000 

 

307,500 

 

507,500 

Granted in 2016

 

 

Expired in 2016

(150,000)

 

(60,000)

 

(210,000)

 

 

 

 

 

 

Balance, December 31, 2016

50,000 

 

247,500 

 

297,500 

Granted in 1Q, 2Q and 3Q 2017

 

 

Cancelled in 1Q, 2Q and 3Q 2017

 

 

 

 

 

 

 

 

Balance, September 30, 2017

50,000 

 

247,500 

 

297,500 

  Shares of Common Stock Exercisable Into 
  Stock       
  Options  Warrants  Total 
Balance, December 31, 2017  50,000   247,500   297,500 
Granted in 2018  6,000,000   2,850,000   8,850,000 
Cancelled in 2018  -   -   - 
Exercised in 2018  -   (850,000)  (850,000)
             
Balance, December 31, 2018  6,050,000   2,247,500   8,297,500 
Granted in Q1 2019  -   -   - 
Cancelled in Q1 2019  -   -   - 
Exercised in Q1 2019  -   -   - 
             
Balance, March 31, 2019  6,050,000   2,247,500   8,297,500 


18

Issued and outstanding stock options as of September 30, 2017March 31, 2019 consist of:


Year

 

Number Outstanding

 

 

Exercise

 

Year of

Granted

 

And Exercisable

 

 

Price

 

Expiration

2009

 

50,000

 

 

1.00

 

2019

 

 

 

 

 

 

 

 

Total

 

50,000

 

 

 

 

 





Year Number Outstanding  Exercise  Year of 
Granted And Exercisable  Price  Expiration 
          
2009  50,000  $1.000   2019 
2018  6,000,000  $0.001   2023 
             
Total  3,050,000         


On June 11, 2018, the Company granted 3,000,000 options of CANB common stock to Carl Dilley, a former director of the Company, in exchange for the retirement of a total of 3,000,000 shares of CANB common stock from Carl Dilley. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire June 11, 2023. The value of the Stock Options ($84,000) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.028 share price, (ii) 5 years term, (iii) 262.00% expected volatility, (iv) 2.80% risk free interest rate and the difference between this value and the fair value of retired shares was expensed in the quarterly period ended June 30, 2018.

On October 21, 2018, the Company granted 3,000,000 options of CANB common stock to Stanley L. Teeple, an officer and Director of the Company. The options are exercisable for the purchase of one share of the Registrant’s Common Stock at an exercise price of $0.001 per share. The Options are fully vested and are exercisable as of the Grant Date and all shall expire October 1, 2023. The values of the Stock Options ($118,200) were calculated using the Black Scholes option pricing model and the following assumptions: (i) $0.0395 share price, (ii) 5 years term, (iii) 221.96% expected volatility, (iv) 3.05% risk free interest rate and the fair value of options was expensed in the quarterly period ended December 31, 2018

Issued and outstanding warrants as of September 30, 2017March 31, 2019 consist of:


Year

 

Number Outstanding

 

 

Exercise

 

Year of

 Number Outstanding Exercise  Year of 

Granted

 

And Exercisable

 

 

Price

 

Expiration

 And Exercisable  Price  Expiration 
        

2010

 

247,500

 

 

1.00

 

2020

  247,500  $1.00   2020 
2018  2,000,000  $0.04345(a)  2023 

 

 

 

 

 

 

 

            

Total

 

247,500

 

 

 

 

 

  2,247,500         


(a) 110% of the closing price of the Company’s common stock on the date that the Holder funds the full purchase price of the Note.

NOTE 1113 – Income Taxes


No provisions for income taxes were recorded for the periods presented since the Company incurred net losses in those periods.


19

The provisions for (benefits from) income taxes differ from the amounts determined by applying the U.S. Federal income tax rate of 21% and 35% to pretax income (loss) as follows:


 Three Months March 31, 

 

Nine Months Ended September 30,

 2019  2018 

 

2017

 

2016

     

Expected income tax (benefit) at 35%

$

(163,186)

 

$

(119,750)

Expected income tax (benefit) at 21% $(246,228) $85,587 

 

 

 

 

        

Non-deductible stock-based compensation

Non-deductible stock-based compensation

39,703 

 

10,500 

  173,921   90,449 

 

 

 

 

        

Non-deductible amortization of debt discounts

Non-deductible amortization of debt discounts

76,751 

 

  -   5,977 

 

 

 

        

Non-taxable (income) from derivative liability

(76,869)

 

Non-deductible expense from derivative liability  -   (225,898)

 

 

 

        

Increase in deferred income tax assets

valuation allowance

 

123,601 

 

109,250 

  72,307   43,885 

 

 

 

 

        

Provision for (benefit from) income taxes

 

$

 

$

 $-  $- 


Deferred income tax assets consist of:

 

 

September 30,

 2017

 

December 31, 2016

Net operating loss carryforward

 

1,344,080 

 

1,220,479 

 

 

 

 

 

Valuation allowance

 

(1,344,080)

 

(1,220,479)

 

 

 

 

 

Net

 

$

 

$


  March 31,  December 31, 
  2019  2018 
       
Net operating loss carryforward  1,716,900   1,644,593 
         
Valuation allowance  (1,716,900)  (1,644,593)
         
Net $-  $- 

Based on management'smanagement’s present assessment, the Company has not yet determined it to be more likely than not that a deferred income tax asset of $1,344,080$1,716,900 attributable to the future utilization of the $3,829,650$5,131,252 net operating loss carryforward as of September 30, 2017December 31, 2018 will be realized. Accordingly, the Company has maintained a 100% allowance against the deferred income tax asset in the consolidated financial statements at September 30, 2017.March 31, 2019. The Company will continue to review this valuation allowance and make adjustments as appropriate. The net operating loss carryforward expires in years 2025, 2026, 2027, 2028, 2029, 2030, 2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038 and 20372039 in the amount of $1,369, $518,390, $594,905, $686,775, $159,141, $151,874, $135,096, $166,911, $311,890, $25,511, $338,345, $386,297, $496,798, $713,162 and $353,146,$344,318, respectively.

 

Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited.


The Company'sCompany’s U.S. Federal and state income tax returns prior to 2014 are closed and management continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The statute of limitations on the 20132014 tax year returns expired in March 2017.September 2018.

 

The Company recognizes interest and penalties associated with uncertain tax positions as part of the income tax provision and would include accrued interest and penalties with the related tax liability in the consolidated balance sheets. There were no interest or penalties paid during 20172018 and 2016.2017.





20


NOTE 1214 – Commitments and Contingencies


Employment Agreements


On May 14, 2015,October 3, 2017, the Company executed an Executive Employment Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi to serve as the Company'sCompany’s chief executive officer and interim chief financial officer and secretary for cash compensation of $5,000$10,000 per month (increased to $6,000 per month in August 2015).month. Pursuant to the agreement, the Company issued 10,000,000 restricted sharesa share of CANB common stockSeries A Preferred Stock to Alfonsi on June 14, 2015.October 4, 2017 (see Note 8). Alfonsi may terminate his employment upon 30 days written notice to the Company. The Company may terminate Alfonsi'sAlfonsi’s employment upon written notice to Alfonsi by a vote of the Board of Directors. At November 12, 2018, this Agreement was terminated due to the execution of a new Employment Agreement with Marco Alfonsi for Alfonsi to serve as the Company’s chief executive officer for cash compensation of $15,000 per month. Pursuant to the agreement, three of the eight previously issued shares of CANB Series A Preferred Stock will be returned to the Company and converted into 30,000,000 common shares. On December Alfonsi may terminate his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Alfonsi, and also can be terminated by the Company due to the failure or neglect of Mr. Alfonsi to perform his duties, or due to the misconduct of Mr. Alfonsi in connection with the performance.


On August 17, 2015,February 12, 2018, the Company executed an Executive Service Agreement (“Agreement”) with David Posel. The Agreement provides that Mr. Posel services as the Company’s Chief Operating Officer for a term of 4 years. The Agreement also provides for compensation to Mr. Posel of $5,000 cash per month and the issuance of 1 share of Series A Preferred Stock at the inception of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Posel, and also can be terminated by the Company due to the failure or neglect of Mr. Posel to perform his duties, or due to the misconduct of Mr. Posel in connection with the performance. On February 12, 2018, 1 share of CANB Series A Preferred Stock were issued to Mr. Posel (see Note 8). Since execution of the Posel Agreement, Mr. Posel has been re-assigned to COO for Pure Health Products, the Company’s subsidiary.

On February 16, 2018, the Company executed an Executive Service Agreement (“Agreement”) with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 3 years. The Agreement also provides for compensation to Mr. Holtmeyer of $10,000 cash per month and the issuance of 3, 2 and 1 share of Series A Preferred Stock at the beginning of each year. The Agreement can be terminated upon the resignation or death of Mr. Holtmeyer, and also can be terminated by the Company due to the failure or neglect of Mr. Holtmeyer to perform his duties, or due to the misconduct of Mr. Holtmeyer in connection with the performance. At December 29, 2018, this Agreement was terminated due to the execution of a new Employment Agreement with Andrew W Holtmeyer. The Agreement provides that Mr. Holtmeyer services as the Company’s Executive Vice President Business for a term of 4 years. The Agreement also provides for compensation to Mr. Holtmeyer of $15,000 cash per month and the issuance of 245,789 shares of common stock upon signing of the agreement.

On October 15, 2018, the Company executed an Employment Agreement (“Agreement”) with Romuald Stone ("Stone"Stanley L. Teeple. The Agreement provides that Mr. Teeple services as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Agreement also provides for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock upon execution of the Agreement. The Agreement can be terminated upon the resignation or death of Mr. Teeple, and also can be terminated by the Company due to the failure or neglect of Mr. Teeple to perform his duties, or due to the misconduct of Mr. Teeple in connection with the performance.

On December 28, 2018, the Company executed an Employment Agreement (“Agreement”) with Pasquale Ferro for StoneMr. Ferro to serve as the Company's Chief Technology OfficerPure Health Products’ president for cash compensation of $12,500$15,000 per month. Effective August 17, 2016,month and the agreement terminated.total issuance of 5 share of Series A Preferred Stock proportionately vesting at the beginning of each year for a term of 4 years. Mr. Ferro may terminate his employment upon 30 days written notice to the Company. The Agreement has an initial term of four years and can be terminated upon the resignation or death of Mr. Ferro, and also can be terminated by the Company due to the failure or neglect of Mr. Ferro to perform his duties, or due to the misconduct of Mr. Ferro in connection with the performance.


21

Consulting Agreements


On September 6, 2017, the Company executed a Consulting Agreement with T8 Partners LLC (“T8”) for T8 to serve as the Company'sCompany’s consultant for stock compensation of a total of 10,000,000 restricted shares. Pursuant to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to T8 on September 7, 2017. Effective October 27, 2017, the Company terminated the agreement due to non-performance by T8. The Company won the arbitration proceedings against T8 and T8 has been ordered to return its shares to the Company.


On November 9, 2017, the Company executed a Consulting Agreement with Healthcare Advisory Group Company (“Healthcare”) for Healthcare to serve as the Company’s consultant for stock compensation of a total of 5,000,000 restricted shares. Pursuant to the agreement, the Company issued 2,500,000 restricted shares of CANB common stock to Healthcare on November 9, 2017. Effective March 6, 2018, the Company terminated the agreement due to non-performance by Healthcare.

Lease Agreements


On December 1, 2014, Prosperity entered into a lease agreement with KLAM, Inc. for office space in Hicksville, New York for an initial term of one year commencing December 1, 2014. The lease provides for monthly rentals of $2,500 and provides Prosperity an option to renew the lease after the initial term. The Company has continued to occupy this space after November 30, 2015 under a month to month arrangement at $2,500 per month. KLAM, Inc. is controlled by the wife of the Company'sCompany’s chief executive officer Marco Alfonsi.


On September 11, 2015, the Company executed a lease agreement with an unrelated third party for office space in Hicksville, New York for a term of 37 months. The lease provides for monthly rentals of $2,922 for lease year 1, $3,009 for lease year 2, and $3,100 for lease year 3. The lease also provides for additional rent based on increases in base year operating expenses and real estate taxes. On August 6, 2018, the Company renewed the lease agreement for a term of 36 months starting November 1, 2018. The lease provides for monthly rentals of $3,193 for lease year 1, $3,289 for lease year 2, and $3,388 for lease year 3.


Rent expense for the year ended December 31, 2018 and 2017 was $48,795 for each of the nine months ended September 30, 2017$67,165 and 2016.$65,060, respectively.


At September 30, 2017,March 31, 2019, the future minimum lease payments under non-cancellable operating leases were:


Year ending December 31, 2017

9,391

Year ending December 31, 2018

27,900

Year ended December 31, 2019  28,932 
Year ended December 31, 2020  39,666 
Year ended December 31, 2021  33,880 
Total $102,478 

 

Total

$

37,291



The lease liability of $90,591 at March 31, 2019 as presented in the Consolidated Balance Sheet represents the discounted (at our 10% estimated incremental borrowing rate) value of the future lease payments of 102,478 at March 31, 2019.

Major Customers


For the ninethree months ended September 30, 2017, twoMarch 31, 2019, there were no customers that accounted for more than 10% of total revenues.

For the three months ended March 31, 2018, one customer accounted for approximately 45% and 29%, respectively,13% of total service revenues.


For the nine months ended September 30, 2016, three customers accounted for approximately 36%, 30%, and 15%, respectively, of total service revenues.


Public Offering of Units


On August 2, 2016, the Company’s Registration Statement on Form S-1 was declared effective by the Securities and Exchange Commission. On a self-underwritten basis, the Company was offering up to 40,000,000 Units at a price of $0.05 per Unit or $2,000,000 maximum. Each Unit consisted of one share of Company common stock and one warrant to purchase ½ share of Company common stock of a price of $0.10 per share for a period of three years. There was no minimum offering amount or escrow required as a condition to closing. On May 5, 2017, the Company withdrew the Registration Statement; no units were sold in the offering.






Litigation


On November 25, 2016, the landlord under the lease agreement dated September 11, 2015 (“QPR”) served us a Notice of Default. On December 5, 2016, QPR filed a Petition to Recover Possession of Real Property seeking unpaid rent of $12,540 (as of November 21, 2016) and possession of the premises. The Company subsequently paid QPR and QPR dismissed the action.


NOTE 1315 – Related Party Transactions


ProAdvanced Group, Inc. (“PAG”), an entity controlled by the Company’s chief executive officer, is a customer of CANB. At September 30, 2017,March 31, 2019, CANB had an account receivable from PAG of $1,190.$7,240. For the three months ended March 31, 2019, CANB had revenues from PAG of $0.


Island Stock Transfer (“IST”), an entity controlled by Carl Dilley, a former Company director, is both a customer and vendor of CANB. As of June 30, 2017,At March 31, 2019, CANB had an account receivable from IST of $3,500 and an account payable to IST of $2,351.$7,932. For the ninethree months ended September 30,March 31, 2019, CANB had revenues from IST of $3,500.$0.


Stock Market Manager, Inc. (see Note 5) is also an entity controlled by Mr. Dilley. At September 30, 2017,For the three months ended March 31, 2019, CANB had an account payable to Stock Market Manager Inc. of $1,676.

During the three months ended March 31, 2019, we had products and service sales to related parties totaling $0.


NOTE 1416 – Subsequent Events


On October 3, 2017,From April 29, 2019 to May 1, 2019, the Company issued a Convertible Promissory Note of $2,000 to a lender for loan proceeds of $2,000. The note bears interest at a rate of 12% per annum, are due on May 7, 2018, and is convertible at the option of the lender intoaggregately 4,504,950 shares of the CompanyCANB common stock at a Conversion Price equal to the lesser of (i) $0.01 per share or (ii) 50% of the lowest Closing Bid Price of the Common StockRedDiamond in exchange for the 30 Trading Days preceding the Conversion Date.


On October 3, 2017, the Company executed an Executive Service Agreement with Marco Alfonsi (“Alfonsi”) for Alfonsi to serve as the Company's chief executive officer for cash compensationretirement of $10,000 per month. Pursuant to the agreement, the Company issued 1 share of CANB Series A Preferred Stock to Alfonsi on October 4, 2017.


On October 4, 2017, the Company issued 235,000 shares of CANB Series A Preferred Stock to Alfonsi in consideration of Alfonsi’s cancellation of accrued salaries payable of $120,000 owed to Alfonsi.


On October 13, 2017, the Company executed a Securities Purchase Agreement (the “SPA”) with RedDiamond Partners LLC (“RedDiamond”). Pursuant to the Agreement, RedDiamond agreed to purchase an aggregate of $150,000 of Series B Preferred Shares (“Preferred Shares”), at $0.95 per share, for an aggregate of 157,895 Preferred Shares. The SPA provides for the purchase to be conducted through multiple closings, with the first closing occurring within ninety (90) days from the execution of the Agreement (“First Closing”). On October 13, the Company received $100,000 from RedDiamond. Additional closings are to be conducted on each monthly anniversary following the date of the First Closing (“Additional Closings”) until RedDiamond has purchased an aggregate of $150,000 of Preferred Shares. The Series B Preferred Shares (designated on November 15, 2017) have no voting rights, are entitled to dividends at a rate of 5% per annum, and are convertible into shares of common stock at a Conversion Price (as defined in the SPA), subject to a $20,000 maximum per Monthly Conversion Period.Stock.


On October 17, 2017, November 1, 2017 and November 9, 2017, the Company executed three Consulting Agreements with three consultants. Pursuant to the agreements, the Company issued or is required to issue 500,000 (not yet issued), 250,000 and 2,500,000 shares of CANB Common on October 17, 2017, November 2, 2017, and November 9, 2017, respectively.


On October 17, 2017, the Company was issued a Secured Promissory Note of $60,000 from a Borrower for loan proceeds of $60,000. The note bears interest at a rate of 12% per annum, and is due on October 17, 2018. On November 10, 2017, the Company entered into an Agreement for Sale and Purchase of Business Assets with the borrower to purchase its business assets. The consideration of $60,000 was paid via the cancellation of the Secured Promissory Note.  


In accordance with FASB ASC 855, Subsequent Events, the Company has evaluated subsequent events through NovemberMay 17, 2017,2019, the date on which these consolidated financial statements were available to be issued. Except as disclosed above, there were no material subsequent events that required recognition or additional disclosure in these consolidated financial statements.




22


ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS


General


Canbiola, Inc. was originally formed as a Florida corporation on October 11, 2005, under the name of WrapMail, Inc. Effective January 5, 2015, we acquired 100% ownership of Prosperity Systems, Inc. (“Prosperity”), which the Company is in the process of dissolving. Effective December 28, 2018, we acquired 100% ownership of Pure Health Products. In November 2018, we formed Duramed as a New York corporation incorporated on April 2, 2008. We provide document, project, marketing and sales management systems to business clients through our website and proprietary software and also have a division focusing on the development and sale of products containing CBD.wholly-owned subsidiary. The Company is presently in the process of dissolving Prosperity.


We manufacture and sell products containing CBD. We also provide document, project, marketing and sales management systems to our residual business clients through our website and proprietary software, which divisions are being wound-down. The consolidated financial statements include the accounts of CANB and its wholly owned subsidiary Prosperity fromPure Health Products and DuraMed for the date of its acquisition on January 5, 2015.three months ended March 31, 2019.


Results of Operations


Three Months Ended September 30, 2017March 31, 2019 compared with Three Months Ended September 30, 2016:March 31, 2018:


Revenues decreased $2,229increased $447,391 from $24,327$69,769 in 20162018 to $22,098$517,160 in 2017.2019.


Cost of product sales increased $10,559$217,966 from $0$44,587 in 20162018 to $10,559$262,553 in 20172019 due to the expansion of current product sales and launch of new product sales.sales in Duramed.


Officers and directorsdirector’s compensation increased $182,750 from $262,800 in 2018 to $445,550 in 2019. The 2019 expense amount(445,550) includes stock-based compensation($262,420) paid to officers and payroll taxes decreased $19,520 from $38,897 in 2016 to $19,377 in 2017.employees. The 20162018 expense amount ($38,897) consists of salary262,800) includes stock-based compensation ($202,800) paid to our Chief Technology Officer ($18,750) and Chief Executive Officer ($18,000) pursuant to their respective employment agreements and related payroll taxes ($2,147). The 2017 expense amount ($19,377) consists of salaries accrued to our Chief Executive Officer ($18,000) pursuant to their respective employment agreements and related payroll taxes ($1,377).the advisory board members.


Consulting fees increased $106,065$387,843 from $4,104$275,908 in 20162018 to $110,709$663,751 in 2017.2019. The 20162019 expense amount ($4,104)663,751) includes stock-based compensation of $0.$565,776, resulting from stock issued for the service of consultants. The 20172018 expense amount ($110,709)275,908) includes stock-based compensation of $76,209,$11,000, resulting from stock issued for the service of consultants.


Advertising expense increased $8,251$4,055 from $5,551$22,333 in 20162018 to $13,802$26,388 in 2017.  2019.


Hosting expense decreased $5,393$3,218 from $8,325$3,668 in 20162018 to $2,932$450 in 2017.2019.


Rent expense remained same atdecreased $4,405 from $16,265 in 2016 and 2017.2018 to $11,860 in 2019.


Professional fees decreased $12,080increased $24,453 from $20,050$13,383 in 20162018 to $7,970$37,836 in 2017.2019.


Depreciation of property and equipment increased $1$1,962 from $806$803 in 20162018 to $807$2,765 in 2017.  2019.


Amortization of intangible assets remained same at $993increased $2,194 from $0 in 2016 and 2017.2018 to $2,194 in 2019.


Other operating expenses increased $7,178$171,168 from $13,464$64,713 in 20162018 to $20,642$235,881 in 2017.2019. The increase was due largely to higher conferencereferral fees, travel expense, and travel expensesnews announcement fees in 20172019 compared to 2016.2018.


Net lossincome decreased $102,064$1,580,072 from income of $407,558 in 2018 to a loss of $83,961$1,172,514 in 2016 to an income of $18,103 in 2017.2019. The decrease was due to the $95,601 increase in total operating expenses and the increase of $199,894 in other income – net from $167 other income – net in 2016 to $200,061 other income– net in 2017, and the $2,229 decrease in revenues.


Nine Months Ended September 30, 2017 compared with Nine Months Ended September 30, 2016:


Revenues decreased $6,050 from $71,990 in 2016 to $65,940 in 2017.  


Cost of product sales increased $11,698 from $0 in 2016 to $11,698 in 2017 due to the launch of new product sales.





Officers and directors compensation and payroll taxes decreased $101,254 from $159,463 in 2016 to $58,209 in 2017.  The 2016 expense amount ($159,463) consists of salary paid to our Chief Technology Officer ($93,750,000) and Chief Executive Officer ($54,000) pursuant to their respective employment agreements and related payroll taxes ($11,713). The 2017 expense amount ($58,209) consists of salaries accrued to our Chief Executive Officer ($54,000) pursuant to their respective employment agreements and related payroll taxes ($4,209).


Consulting fees increased $84,018 from $98,473 in 2016 to $182,491 in 2017. The 2016 expense amount ($98,473) includes stock-based compensation of $30,000. The 2017 expense amount ($182,491) includes stock-based compensation of $113,438, resulting from stock issued for the service of consultants.


Advertising expense increased $25,011 from $10,301 in 2016 to $35,312 in 2017.  


Hosting expense decreased $2,846 from $20,465 in 2016 to $17,619 in 2017.


Rent expense remained same at $48,795 in 2016 and 2017.


Professional fees increased $33,919 from $36,787 in 2016 to $70,706 in 2017.


Depreciation of property and equipment decreased $38 from $2,459 in 2016 to $2,421 in 2017.  


Amortization of intangible assets decreased $1 from $2,980 in 2016 to $2,979 in 2017.


Other operating expenses increased $46,250 from $34,911 in 2016 to $81,161 in 2017.  The increase was due largely to higher office expenses and conference expenses in 2017 compared to 2016.


Net loss increased $124,103 from a loss of $342,142 in 2016 to a loss of $466,245 in 2017. The increase was due to the $96,757$766,802 increase in total operating expenses and the decrease of $21,296$1,042,695 in other income – net from $502$1,042,249 other income – net in 20162018 to $20,794$446 other expense– net in 2017, and2019, offset by the $6,050 decrease$447,391 increase in revenues.


23

Liquidity and Capital Resources


At September 30, 2017,March 31, 2019, we had cash and cash equivalents of 4,225$567,291 and negative working capital of $731,850.$1,067,641.


Cash and cash equivalents decreased $25,968$240,456 from $30,193$807,747 at December 31, 20162018 to $4,225$567,291 at September 30, 2017.March 31, 2019. For the ninethree months ended September 30, 2017, $179,250March 31, 2019, $1,194,265 was provided by financing activities, $744,212 was used in investing activities, and $205,218$690,509 was used in operating activities.


We currently have no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.


We currently have no commitments with any person for any capital expenditures.


We have no off-balance sheet arrangements.


ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

None.

 

ITEM 4. CONTROLS AND PROCEDURES

 

(A) EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

 

As of September 30, 2017,March 31, 2019, our principal executive officer and principal financial officer conducted an evaluation regarding the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) under the Exchange Act). Based upon the evaluation of these controls and procedures, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report.

 

(B) CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

 

There were no changes in our internal control over financial reporting in our first fiscal quarter for the period ended September 30, 2017March 31, 2019 covered by this Quarterly Report on Form 10-Q, that have materially affected, or are reasonably likely to materially affect our internal control over financial reporting.





PART II-OTHERII - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

We are not currently a party to any legal proceedings.

 

ITEM 1A. RISK FACTORS

 

As a smaller reporting company, we are not required to provide risk factors in this Form 10-Q.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Sales of unregistered securities during the quarterly period ended September 30, 2017March 31, 2019 follows:


On February 2, 2017,From January 4, 2019 to March 27, 2019, the Company issued 200,000aggregately 41,431,994 shares of CANB common stock to a financial consultant as paymentmultiple investors pursuant to relative Stock Purchase Agreements dated on various dates, in fullexchange for $11,000total proceeds of services rendered for the period January 1, 2016 through March 31, 2017.$1,196,100.


On February 13, 2017,January 14, 2019, the Company issued 1,685,9007,500,000 shares of CANB common stock to the brotherHudilab, Inc. (“HUDI”), pursuant to a License and Acquisition Agreement for purchase of the Chief Executive Officer of the Company in satisfaction of notes payable of $15,000 and accrued interest payable of $1,859.technology owned by HUDI.


24

OnFrom January 18, 2019 to March 22, 2017,17, 2019, the Company issued 6,785,316aggregately 24,600,000 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $5,979.multiple consultants for services rendered.


On April 17, 2017,From January 19, 2019 to March 27, 2019, the Company issued 5,000,000aggregately 1,167,959 shares of CANB common stock to a consultant as paymentemployee and officers of the Company pursuant to employee agreement and in full for $103,500satisfaction of services renderedaccrued compensation for the period April 1, 2016 through June 30, 2017.quarter ended March 31, 2019.


On June 21, 2017,February 5, 2019, the Company issued 250,0002,000,000 shares to the owner of TZ Wholesale LLC, pursuant to a Memorandum of Understanding (the “MOU”) dated November 9, 2018.

On February 20, 2019, the Company issued 1,000,000 shares of CANB common stock to a financial consultant as payment in full for $5,975owners of services rendered for the period April 1, 2016 through June 30, 2017.Seven Chakras pursuant to an Asset Purchase Agreement (the “Agreement”) with Seven Chakras, LLC dated January 31, 2019.


On June 28, 2017, the Company issued 250,000 shares of CANB common stock to a financial consultant as payment in full for $5,000 of services rendered for the period April 1, 2016 through June 30, 2017.


On August 25, 2017, the Company issued 7,142,857 shares of CANB common stock to a lender in satisfaction of notes payable of $50,000 and accrued interest payable of $3,331.


On August 25, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $3,750 fair value of the 250,000 shares of CANB common stock will be partially charged to consulting fees in the three months ended September 30, 2017.


On September 5, 2017, the Company issued 250,000 shares of CANB common stock to a consultant for services rendered. The $4,375 fair value of the 250,000 shares of CANB common stock will be partially charged to consulting fees in the three months ended September 30, 2017.


On September 7, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $32,750 fair value of the 2,500,000 shares of CANB common stock will be charged to consulting fees in the three months ended September 30, 2017.


On September 11, 2017, the Company issued 250,000 and 250,000 shares of CANB common stock to two consultants for services rendered, respectively. The $3,350 fair value of each 250,000 shares of CANB common stock will be partially charged to consulting fees in the three months ended September 30, 2017.


On September 25, 2017, the Company issued 2,500,000 shares of CANB common stock to a consultant for services rendered. The $2,525 fair value of the 2,500,000 shares of CANB common stock will be partially charged to consulting fees in the three months ended September 30, 2017.


With respect to the transactions noted above, each of the recipients of securities of the Company was an accredited investor, or is considered by the Company to be a “sophisticated person”, inasmuch as each of them has such knowledge and experience in financial and business matters that they are capable of evaluating the merits and risks of receiving securities of the Company. No solicitation was made and no underwriting discounts were given or paid in connection with these transactions. The Company believes that the issuance of its securities as described above was exempt from registration with the Securities and Exchange Commission pursuant to Section 4(a)(2) of the Securities Act of 1933.






ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

3.1

3.1

Articles of Incorporation, as amended*

3.2

Bylaws*

31.1

Rule 13a-14(a)/15d-14(a) certification of Chief Executive Officer

certification under Section 302 of the Sarbanes-Oxley Act of 2002

32.1

31.2

Chief Financial Officer certification under Section 1350 certification302 of the Sarbanes-Oxley Act of 2002

32.1Chief Executive Officer

certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

99.1

32.2

AmendmentChief Financial Officer certification pursuant to Articles18 U.S.C. Section 1350, as adopted pursuant to Section 906 of Incorporation and Certificatethe Sarbanes-Oxley Act of Designations for Series B Preferred Stock **

2002

99.2

Certificate of Designations for Series B Preferred Stock***

101.INS

*

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Label Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

*         filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated

herein by reference.


**       filed with the Form 8-K filed with the SEC on November 15, 2017 and incorporated herein by reference.


***     filed with the Form 8-K filed with the SEC on October 18, 2017 and incorporated herein by reference.





25


SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


Date: November 20, 2017 


CANBIOLA, INC.

CANBIOLA, INC.

Date: May 23, 2019

By:

/s/ Marco Alfonsi

Marco Alfonsi, Chief Executive Officer
Date: May 23, 2019By:/s/ Stanley L. Teeple
Stanley L. Teeple, Chief Financial Officer

26




22